跳至主要内容
临床试验/CTRI/2026/07/113692
CTRI/2026/07/113692进行中(未招募)2/3 期

A Randomized Controlled Trial to Evaluate the Efficacy and Safety of Saptanga Guggulu as an Adjunct to Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus - NIL

Dr. Snehal Hindurao Fasake0 个研究点目标入组 68 人开始时间: 2026年7月19日最近更新:

试验速览

阶段
2/3 期
状态
进行中(未招募)
发起方
入组人数
68

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Age group: between 30 years to 60 years.
  • Gender: Male and Female both will be included.
  • A known Diabetic on treatment
  • Fasting Blood Sugar: more than or equal to 126mg per dl and less than or equal to 250mg per dl
  • Post Prandial Blood Sugar: more than 140mg per dl and less than 300mg per dl
  • Patient having HbA1C more than and equal to 10

排除标准

  • IDDM, Acromegaly, Cushing s syndrome and pancreatic disorder.
  • Pregnant and lactating mothers.
  • Patients with K/C/O Nephropathy, Neuropathy and Retinopathy.
  • Patients with gastrointestinal diseases, Liver diseases, tumours, cardio vascular disease, acute myocardial infarction, immune-compromised disease (HIV).

研究者

发起方
Dr. Snehal Hindurao Fasake

相似试验